899790-17-1

Usage

Uses

Used in Pharmaceutical and Agrochemical Industries:
2-(cyclohexylamino)-5-nitrobenzenesulfonamide is used as an intermediate in the synthesis of various pharmaceuticals and agrochemicals for its ability to contribute to the development of new drugs and pesticides. Its presence in these compounds aids in enhancing their therapeutic or pesticidal effects.
Used in Infectious Disease Treatment:
2-(cyclohexylamino)-5-nitrobenzenesulfonamide is used as a potential treatment for various infectious diseases due to its inherent antibacterial and antifungal properties. Research is ongoing to explore its efficacy in combating a range of pathogens.
Used as a Corrosion Inhibitor in Industrial Applications:
In the industrial sector, 2-(cyclohexylamino)-5-nitrobenzenesulfonamide is utilized as a corrosion inhibitor to protect materials from degradation. Its application helps in extending the lifespan of equipment and structures by reducing the rate of corrosion.

Upstream product

• 96-72-0 2-chloro-5-nitrobenzenesulfonamide 
• 108-91-8 cyclohexylamine 
• 4533-95-3 5-nitro-2-chlorobenzenesulfonyl chloride 
• 6283-25-6 H₂NC₆H₃(Cl)NO₂ 

Relevant academic research and scientific papers

Synthesis and pharmacological evaluation of novel nitrobenzenic thromboxane modulators as antiplatelet agents acting on both the alpha and beta isoforms of the human thromboxane receptor

Thromboxane A2 (TXA2) is an arachidonic acid metabolite involved in pathologies such as stroke, myocardial infarction, and atherosclerosis. Consequently, the design of TXA2 receptor (TP) antagonists remains of great interest in cardiovascular medicine. The actions of TXA2 are mediated by its specific G-protein coupled receptor of which two alternative spliced isoforms, TPα and TPβ, have been described in humans. In this study, we report the synthesis of a series of original N-alkyl-N′-[2-(cycloalkyl, alkylaryl)-5-nitrobenzenesulfonyl]urea and N-alkyl-N′-[2-(alkylaryl)-5-nitrobenzenesulfonyl]-N″- cyanoguanidines and outline their pharmacological evaluation using the individual TPα and TPβ isoforms. Among compounds analyzed, several of them exhibited greater affinity and/or functional activity for either TPα or TPβ. The most promising molecules were also found to be antiplatelet agents. From the present results, structural features involved in isoform selectivity can be proposed, and thereby several lead compounds have been identified for the further development of selective TP isoform antagonists.